A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis ; volume:24 ; number:1 ; day:2 ; month:6 ; year:2023 ; pages:1-14 ; date:12.2023
Respiratory research ; 24, Heft 1 (2.6.2023), 1-14, 12.2023
- Creator
-
Imakura, Takeshi
Sato, Seidai
Koyama, Kazuya
Ogawa, Hirohisa
Niimura, Takahiro
Murakami, Kojin
Yamashita, Yuya
Haji, Keiko
Naito, Nobuhito
Kagawa, Kozo
Kawano, Hiroshi
Zamami, Yoshito
Ishizawa, Keisuke
Nishioka, Yasuhiko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-023-02446-x
- URN
-
urn:nbn:de:101:1-2023091312425686467537
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Imakura, Takeshi
- Sato, Seidai
- Koyama, Kazuya
- Ogawa, Hirohisa
- Niimura, Takahiro
- Murakami, Kojin
- Yamashita, Yuya
- Haji, Keiko
- Naito, Nobuhito
- Kagawa, Kozo
- Kawano, Hiroshi
- Zamami, Yoshito
- Ishizawa, Keisuke
- Nishioka, Yasuhiko
- SpringerLink (Online service)
Other Objects (12)
Drug repositioning
Targeting Neuraminidase 4 Attenuates Kidney Fibrosis in Mice
Metformin attenuates lung fibrosis development via NOX4 suppression
Targeting Ferroptosis Attenuates Interstitial Inflammation and Kidney Fibrosis
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
Kangxianling formula attenuates renal fibrosis by regulating gut microbiota
Delayed administration of suramin attenuates peritoneal fibrosis in rats
Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ
TRPM8 deficiency attenuates liver fibrosis through S100A9-HNF4α signaling
Drug repositioning
Targeting Neuraminidase 4 Attenuates Kidney Fibrosis in Mice
Metformin attenuates lung fibrosis development via NOX4 suppression
Targeting Ferroptosis Attenuates Interstitial Inflammation and Kidney Fibrosis
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
Kangxianling formula attenuates renal fibrosis by regulating gut microbiota
Delayed administration of suramin attenuates peritoneal fibrosis in rats
Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ
TRPM8 deficiency attenuates liver fibrosis through S100A9-HNF4α signaling
Drug repositioning
Targeting Neuraminidase 4 Attenuates Kidney Fibrosis in Mice
Metformin attenuates lung fibrosis development via NOX4 suppression
Targeting Ferroptosis Attenuates Interstitial Inflammation and Kidney Fibrosis
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
SBE13, a newly identified inhibitor of inactive polo-like kinase 1
Kangxianling formula attenuates renal fibrosis by regulating gut microbiota
Delayed administration of suramin attenuates peritoneal fibrosis in rats
Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ